


## AMENDMENTS

### In the Claims:

Claims 1-2. (Canceled).

3. (Currently amended) A compound of formula II,



wherein

Ar<sup>1</sup> is selected from the group consisting of phenyl, pyridinyl, quinolinyl, isoquinolinyl, thiophenyl, benzothiadiazolyl, isoxazolyl and oxazolyl;

Ar<sup>2</sup> is pyridinyl,

R<sup>6</sup>, R<sup>7</sup> are independently H or A,

R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are independently selected from the group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH<sub>2</sub>Hal, CH(Hal)<sub>2</sub>, C(Hal)<sub>3</sub>, NO<sub>2</sub>, (CH<sub>2</sub>)<sub>n</sub>CN, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>O(CH<sub>2</sub>)<sub>k</sub>NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>(CH<sub>2</sub>)<sub>k</sub>NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>O(CH<sub>2</sub>)<sub>k</sub>OR<sup>11</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>(CH<sub>2</sub>)<sub>k</sub>OR<sup>12</sup>,

(CH<sub>2</sub>)<sub>n</sub>COOR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>COR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>CONR<sup>11</sup>R<sup>12</sup>,  
(CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>COR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>CONR<sup>11</sup>R<sup>12</sup>,  
(CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>SO<sub>2</sub>A, (CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>S(O)<sub>u</sub>R<sup>13</sup>,  
(CH<sub>2</sub>)<sub>n</sub>OC(O)R<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>COR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>SR<sup>11</sup>, CH=N-OA,  
CH<sub>2</sub>CH=N-OA, (CH<sub>2</sub>)<sub>n</sub>NHOA, (CH<sub>2</sub>)<sub>n</sub>CH=N-R<sup>11</sup>,  
(CH<sub>2</sub>)<sub>n</sub>OC(O)NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>COOR<sup>13</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>11</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>11</sup>)CH<sub>2</sub>CH<sub>2</sub>OCF<sub>3</sub>,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>11</sup>)C(R<sup>13</sup>)HCOOR<sup>12</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>11</sup>)C(R<sup>13</sup>)HCOR<sup>11</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>11</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>12</sup>)CH<sub>2</sub>COOR<sup>11</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>11</sup>)CH<sub>2</sub>CH<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, CH=CHCOOR<sup>13</sup>,  
CH=CHCH<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, CH=CHCH<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>,  
CH=CHCH<sub>2</sub>OR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>N(COOR<sup>13</sup>)COOR<sup>14</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(CONH<sub>2</sub>)COOR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>N(CONH<sub>2</sub>)CONH<sub>2</sub>,  
(CH<sub>2</sub>)<sub>n</sub>N(CH<sub>2</sub>COOR<sup>13</sup>)COOR<sup>14</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(CH<sub>2</sub>CONH<sub>2</sub>)COOR<sup>13</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(CH<sub>2</sub>CONH<sub>2</sub>)CONH<sub>2</sub>, (CH<sub>2</sub>)<sub>n</sub>CHR<sup>13</sup>COR<sup>14</sup>,  
(CH<sub>2</sub>)<sub>n</sub>CHR<sup>13</sup>COOR<sup>14</sup>, (CH<sub>2</sub>)<sub>n</sub>CHR<sup>13</sup>CH<sub>2</sub>OR<sup>14</sup>, (CH<sub>2</sub>)<sub>n</sub>OCN  
and (CH<sub>2</sub>)<sub>n</sub>NCO, wherein

R<sup>11</sup>, R<sup>12</sup> are independently selected from the group consisting of H, A and (CH<sub>2</sub>),

R<sup>13</sup>, R<sup>14</sup> are independently selected from the group consisting of H, Hal, A and (CH<sub>2</sub>)<sub>m</sub>Ar<sup>4</sup>,

A is selected from the group consisting of alkyl, alkenyl, cycloalkyl, alklenecycloalkyl, alkoxy and alkoxyalkyl,

$\text{Ar}^3, \text{Ar}^4$  are independently aromatic hydrocarbon residues comprising 5 to 12 carbon atoms which are optionally substituted by one or more substituents, selected from the group consisting of A, Hal,  $\text{NO}_2$ , CN,  $\text{OR}^{15}$ ,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{COOR}^{15}$ ,  $\text{CONR}^{15}\text{R}^{16}$ ,  $\text{NR}^{15}\text{COR}^{16}$ ,  $\text{NR}^{15}\text{CONR}^{15}\text{R}^{16}$ ,  $\text{NR}^{16}\text{SO}_2\text{A}$ ,  $\text{COR}^{15}$ ,  $\text{SO}_2\text{R}^{15}\text{R}^{16}$ ,  $\text{S(O)}_u\text{A}$  and  $\text{OOCR}^{15}$ ,

$\text{R}^{15}, \text{R}^{16}$  are independently selected from the group consisting of H, A, and  $(\text{CH}_2)_m\text{Ar}^6$ , wherein

$\text{Ar}^6$  is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from the group consisting of methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH,  $\text{NH}_2$  and  $\text{CF}_3$ ,

k, n and m are independently of one another 0, 1, 2, 3, 4, or 5;

X is O or  $\text{CH}_2$ ,

Y is O or S selected from O and S,

p, r are independently 0, 1, 2, 3, 4 or 5,




q is 0, 1, 2, 3 or 4,






u is 0, 1, 2 or 3,






and


Hal is selected from the group consisting of F, Cl, Br and I;  
and a pharmaceutically acceptable salt derivatives, salts and solvates thereof.


4. (Currently Amended) The compound according to claim 3, selected from the compounds of formula IIc, IIe, IIg, IIh, III, III and IIj, IIk, IIl, IIm, IIn, IIo, IIp, IIq, IIr, IIs, IIt, IIu, IIv, IIw and IIx,











wherein R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, p, Ar<sup>1</sup>, Y, X, R<sup>9</sup>, R<sup>10</sup> and q are as defined in claim 3  
and a pharmaceutically acceptable salt thereof pharmaceutically  
acceptable salts and solvates thereof.

5. (Currently amended) The compound according to claim 4-3, selected from the compounds (1) to (2), (5) to (224) of table 1, the compounds (225) to (226), (229) to (448) (449) of table 2 and/or the compounds (449) (450) to (450) and (453) to (672) of table 3, and a pharmaceutically acceptable salt thereof  
pharmaceutically acceptable salts and solvates thereof.

Claims 6-9. (Canceled).

10. (Currently Amended) A pharmaceutical composition, comprising the compound according to claim 3 in a pharmaceutical composition and further  
comprising an inert carrier.

Claims 11-29. (Canceled).

30. (Withdrawn/Previously presented) A method for producing compounds of formula II, wherein

a) a compound of formula III




wherein

FG is a functional group, selected from  
-N=C=Y and -NH-(C=Y)-LG,  
wherein Y is as defined as in claim 3 and LG is a leaving group,

is reacted

b) with a compound of IV,



wherein

$L^2, L^3$  are independently from one another H or a metal ion, and  $R^6, R^7$ ,  
 $E, G, M, Q, U, R^9, q, X, Ar^2, R^{10}$  and r are as defined in claim 3,

and optionally

- c) isolating and/or treating the compound of formula II obtained by said reaction with an acid, to obtain the salt thereof.

Claims 31-32. (Canceled).